Kramer Levin Naftalis & Frankel LLP attorneys discuss the
direction of biosimilar litigation from recent federal court
rulings. They also look at trends in patent litigation and what to
expect in 2021 and beyond.
The Biologics Price Competition and Innovation Act (BPCIA)
turned 10 this year, making it a good time to look at recent
litigation trends and assess what's ahead for 2021.
U.S. biosimilar
litigation continues to take shape, although most cases have
resolved without a decision on the merits. The U.S. Court of
Appeals for the Federal Circuit has provided guidance on the
requirements for the BPCIA's 180-day notice of commercial
marketing and biosimilar injunctions.
Manufacturing patents protecting all aspects of the manufacture
of biologics continue to play a central role in biosimilar
litigation, as biosimilar makers are obtaining patents to protect
their products and gain a competitive edge.